Antimicrobial resistance in gonorrhoea: Rising threat to treatment efficacy

  11 June 2024

The European Union/European Economic Area (EU/EEA) has reported a 48% increase in confirmed cases of gonorrhoea in 2022, with two isolates resistant to ceftriaxone, the recommended antibiotic for treating the disease. The rise in resistance to azithromycin and ciprofloxacin is concerning, as they are often used alongside ceftriaxone. The ECDC recommends enhanced surveillance, quality-assured antimicrobial susceptibility surveillance, and regular review of treatment guidelines. Investing in developing new antimicrobial treatments and alternative regimens is also crucial. Strengthening public health initiatives, including increased access to diagnostic services, and fostering international cooperation are also recommended. Prevention, including safe sexual practices, testing for sexually transmitted infections, and prudent use of antimicrobials, is also crucial to curb the spread of gonorrhoea.

Further reading: ECDC
Author(s): ECDC
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed